TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy
Brief Summary: The purpose of this study is to determine whether, in patients with chronic proteinuric nephropathy and dyslipidemia, ezetimibe-simvastatin combined therapy is more effective than statin alone to achieve the optimum lipid control, and if this translates to an improvement of the markers of vascular damage. Thirty hypertensive patients in stable therapy with RAS inhibitors, with low-density lipoprotein (LDL) cholesterol superior to 100 mg/ml, are treated with three different hypolipidemic regimens: Simvastatin alone (40 mg/day) or ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day).


Options:
A: Arm Label: simvastatin + ezetimibe; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): simvastatin + ezetimibe
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: EZE/simvastatin | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: EZE/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: EZE/simvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EZE/simvastatin; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: Statin (simvastatin); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age
Brief Summary: Double-blind, multinational, multicentre, randomized, 2-arm parallel-group study


Options:
A: Arm Label: Beclometasone/formoterol (100/6 µg); Type: EXPERIMENTAL; Interventions: Drug: beclometasone /formoterol | Arm Label: salbutamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ventolin | Intervention Type: DRUG; Name: Ventolin; Assigned to Arm(s): salbutamol | Intervention Type: DRUG; Name: beclometasone /formoterol; Assigned to Arm(s): Beclometasone/formoterol (100/6 µg)
B: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A
C: Arm Label: Symbicort "as needed"+placebo Pulmicort bid; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid | Arm Label: terbutaline "as needed"+placebo Pulmicort bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline 'as needed' + placebo budesonide bid | Arm Label: Pulmicort bid + terbutaline "as needed"; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide bid + terbutaline 'as needed' | Intervention Type: DRUG; Name: budesonide/formoterol 'as needed' + budesonide placebo bid; Assigned to Arm(s): Symbicort "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: terbutaline 'as needed' + placebo budesonide bid; Assigned to Arm(s): terbutaline "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: budesonide bid + terbutaline 'as needed'; Assigned to Arm(s): Pulmicort bid + terbutaline "as needed"
D: Intervention Type: DRUG; Name: budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sildenafil for Improving Outcomes After Valvular Correction
Brief Summary: The purpose of this study is to evaluate the clinical efficacy of the mid-term treatment with sildenafil in patients with persistent moderate or severe pulmonary hypertension (PH) after a heart valve intervention.


Options:
A: Arm Label: Sildenafil 40mg or 80mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil 40mg or 80mg
B: Arm Label: Sildenafil High dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil Low dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil medium dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil - Open label Phase; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil High dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil Low dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil medium dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil - Open label Phase
C: Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): N/A
D: Arm Label: Sildenafil Citrate; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Sildenafil Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose
Brief Summary: The purpose of this study is to determine the efficacy of switching to a combination tablet ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin dose in those patients who have cardiovascular disease and diabetes mellitus not adequately controlled on simvastatin 20 mg or atorvastatin 10 mg.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4
C: Arm Label: Experimental: Rosuvastatin + enoxaparin arm; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin 20mg/d for 14days | Arm Label: enoxaparin only; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin only | Intervention Type: DRUG; Name: Rosuvastatin 20mg/d for 14days; Assigned to Arm(s): Experimental: Rosuvastatin + enoxaparin arm | Intervention Type: DRUG; Name: enoxaparin only; Assigned to Arm(s): enoxaparin only
D: Arm Label: Ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Doubling statin dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin 40 mg or atorvastatin 20 mg, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): Ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin 40 mg or atorvastatin 20 mg; Assigned to Arm(s): Doubling statin dose | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: atorvastatin 10 mg or simvastatin 20 mg; Assigned to Arm(s): Doubling statin dose, Ezetimibe/simvastatin, Rosuvastatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Bioequivalence study of SPARC147609


Options:
A: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SPARC147609 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reference147609 | Intervention Type: DRUG; Name: SPARC147609; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Reference147609; Assigned to Arm(s): 2
C: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
D: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Placebo-controlled Clinical Trial Comparing Fesoterodine to Placebo in Women Diagnosed With Urge Urinary Incontinence by the 3 Incontinence Questions (3IQ). Followed by a Multi-center Open Label Clinical Cohort Study of Long-term Effects of Treatment With Fesoterodine.
Brief Summary: Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the US. All participants who complete the 12-week randomized trial will be offered open-label fesoterodine for an additional 9 months.

The hypothesis of the randomized controlled trial is that among women diagnosed with urge incontinence using the 3IQ, fesoterodine is more effective than placebo in reducing the mean number of urge incontinence episodes per day.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tolterodine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: bladder training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor muscle training | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor rehabilitation | Intervention Type: PROCEDURE; Name: tolterodine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: bladder training; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: pelvic floor muscle training; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: pelvic floor rehabilitation; Assigned to Arm(s): 4
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Control
C: Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): N/A
D: Arm Label: Solifenacin; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin | Arm Label: Oxybutynin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin; Assigned to Arm(s): Solifenacin | Intervention Type: DRUG; Name: Oxybutynin; Assigned to Arm(s): Oxybutynin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study
Brief Summary: This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or peritoneum. A total of approximately 5 national centers will participate in phase I of the study. If the starting criteria for phase II of the study are met at the end of phase I, a total of approximately 20 national centers will participate in phase II of the study.


Options:
A: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
B: Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1
D: Arm Label: vargatef/Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: vargatef | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vargatef; Assigned to Arm(s): vargatef/Nintedanib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study
Brief Summary: This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or peritoneum. A total of approximately 5 national centers will participate in phase I of the study. If the starting criteria for phase II of the study are met at the end of phase I, a total of approximately 20 national centers will participate in phase II of the study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1
B: Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: MM-121 (SAR256212) + Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: MM-121, Drug: Paclitaxel | Intervention Type: DRUG; Name: MM-121; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel, Paclitaxel
C: Intervention Type: DRUG; Name: erlotinib hydrochloride; Assigned to Arm(s): N/A
D: Arm Label: Lapatinib Oral Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Intervention Type: DRUG; Name: Oral lapatinib tablets or placebo tablets; Assigned to Arm(s): Lapatinib Oral Tablets, Placebo Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy
Brief Summary: Neuropathy results from damage to the nerves in the feet and legs. It is usually experienced as pain, tingling or numbness. In HIV-infected people, neuropathy can result from the infection itself or be a side effect of antiretroviral treatment. The purpose of this study is to determine whether two different drugs, methadone and duloxetine, reduce neuropathy-associated pain in HIV-infected people. This study will also examine whether utilization of both of these drugs is more effective than treatment with only one.


Options:
A: Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Duloxetine placebo; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Methadone placebo; Assigned to Arm(s): 1, 2, 3, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Brief Summary: The purpose of this study is to compare the effectivity and safety of atrial fibrillation ablation, in comparison to antiarrhythmic drug therapy in patients with refractory, persistent atrial fibrillation.


Options:
A: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
B: Arm Label: Rate control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medication to control ventricular rate in AF | Arm Label: Catheter Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter Ablation for Persistent Atrial Fibrillation | Intervention Type: DRUG; Name: Medication to control ventricular rate in AF; Assigned to Arm(s): Rate control | Intervention Type: PROCEDURE; Name: Catheter Ablation for Persistent Atrial Fibrillation; Assigned to Arm(s): Catheter Ablation
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: Arctic Front® Cryoablation Catheter | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flecainide or Sotalol or Propafenone | Intervention Type: DEVICE; Name: Arctic Front® Cryoablation Catheter; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Flecainide or Sotalol or Propafenone; Assigned to Arm(s): Control
D: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter

Answer: A